Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, registered for an initial public offering Monday morning. The Maryland-based company has three product candidates in Phase I or II testing. UBS Investment Bank and SG Cowen are the lead underwriters on the deal. Terms and timing have yet to be announced.
